BioCentury
ARTICLE | Company News

Lanthio partners with MorphoSys to develop lantipeptide library

November 28, 2012 1:56 AM UTC

Lanthio Pharma B.V. (Groningen, the Netherlands) partnered with MorphoSys AG (Xetra:MOR; Pink:MPSYF) to co-develop Lanthio Pharma's LanthioPep technology to create lantipeptide-based libraries. LanthioPep uses the Lactococcus lactis bacterium to generate lantipeptides, which are peptides constrained by lanthionine bridges that are resistant to degradation, structured to improve efficacy and can be administered via oral, pulmonary or subcutaneous delivery. MorphoSys has the right to exclusively license the LanthioPep technology for drug discovery. The companies did not disclose financial details (see BioCentury, Feb. 20). ...